Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EX19
|
| gptkbp:brand |
gptkb:Tepmetko
|
| gptkbp:CASNumber |
1110733-69-1
|
| gptkbp:chemicalClass |
quinoline derivative
|
| gptkbp:developedBy |
gptkb:Merck_KGaA
|
| gptkbp:hasMolecularFormula |
C29H28N6O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tepotinib
|
| gptkbp:indication |
MET exon 14 skipping mutation-positive NSCLC
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
MET inhibitor
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3544943
46224516 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea edema fatigue increased creatinine |
| gptkbp:target |
gptkb:MET_receptor
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|